Inflammatory bowel disease (IBD) pathogenesis is associated with gut mucosal
inflammation, epithelial damage, and dysbiosis leading to a dysregulated gut mucosal …

Abstract Background Mesenchymal stem cells (MSCs) therapy is a novel treatment strategy
for cancer and a wide range of diseases with an excessive immune response such as …

Inflammatory bowel diseases (IBDs) treatments have shifted from small-molecular
therapeutics to the oncoming biologics. The first-line biologics against the moderate-to …

Inflammatory bowel disease (IBD) is a chronic immune-mediated condition of the
gastrointestinal tract that requires chronic treatment and strict surveillance. Development of …

Biologicals have dominated the therapeutic scenery in inflammatory bowel diseases (IBDs),
namely ulcerative colitis (UC) and Crohn's disease (CD), for the past 20 years. The …

Background Damage to the healthy intestinal epithelial layer and regulation of the intestinal
immune system, closely interrelated, are considered pivotal parts of the curative treatment …

The Janus kinase (JAK) signal transducer and activator of transcription (JAK-STAT) pathway
is an evolutionarily conserved mechanism of transmembrane signal transduction that …

BACKGROUND The exopolysaccharides (EPS) produced by Lactobacillus and other
probiotics are associated with many benefits, such as immune regulation, antioxidant …

Objective Tumour necrosis factor signalling via the receptor-interacting protein kinase 1
(RIPK1) pathway regulates colonic inflammation suggesting that RIPK1 inhibition may be a …

Inflammatory bowel disease (IBD) is a prominent global public health issue. Anti-
inflammatory medications, immunosuppressants, and biological therapies are currently used …